

Meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines

Atlanta, GA, USA
11 November 2006

Immunization, Vaccines and Biologicals

Meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines

Atlanta, GA, USA
11 November 2006

Immunization, Vaccines and Biologicals

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This document was produced by the
Initiative for Vaccine Research
of the Department of Immunization, Vaccines and Biologicals

Ordering code: WHO/IVB/07.11
Printed: November 2007

This publication is available on the Internet at:
www.who.int/vaccines-documents/

**Copies of this document as well additional materials on
immunization, vaccines and biologicals may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland

• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Acknowledgements</i>	<i>vii</i>
<i>Preface</i>	<i>ix</i>
1. Reports from vaccine developers	1
2. Update: Guidelines for the dengue plaque reduction neutralization test	10
3. Update: Establishment of a dengue serum panel for assay validation	11
4. General discussion	13
5. Closed session and final recommendations	14
Annex 1: List of participants	15

Abbreviations and acronyms

AE	Adverse Events
ALT	Acute Liver Toxicity
AST	Acute Systemic Toxicity
CDC	Centers for Disease Control and Prevention
CMI	Cell Mediated Immunity
CPK	Creatine Phosphokinase
CYD	Chimerax-DEN
DEN	Dengue
DNA	Deoxyribonucleic acid
ECBS	Expert Committee on Biologicals Standardization
ELISA	Enzyme Linked ImmunoSorbent Assay
FDA	Food and Drug Administration
GMT	Geometric Mean Titre
HLA	Human Leukocyte Antigen
IFN	Interferon
IgG	Immunoglobulin M
IgM	Immunoglobulin G
IRB	Institutional Review Board
JE	Japanese Encephalitis
NHP	Non-human Primates
NIBSC	National Institute for Biological Standards and Control
NS	Non Structural
Nt	Nucleotide
PBMC	Peripheral Blood Mononuclear Cell
PBS	Phosphate Buffered Saline
PDK	Primary Dog Kidney
PDVI	Pediatric Dengue Vaccine Initiative
PFU	Plaque Forming Unit
PI	Principal Investigator
prM	Pre-Membrane
PRNT	Plaque Reduction Neutralization Test
RT-PCR	Reverse Transcriptase Polymerase Chain Reaction

SAE	Serious Adverse Events
SC	Steering Committee
SCID-HuH	Severe Combined Immunodeficient mouse-human
TCID	Tissue Culture Infective Dose
Th	T Helper
TNF?	Tumor Necrosis Factor Alpha
TSE	Transmissible Spongiform Encephalopathy
US NIH	United States National Institutes of Health
UTR	Untranslated Region
WBC	White Blood Cells
WN	West Nile
WRAIR	Walter Reed Army Institute of Medical Research
YF	Yellow Fever

Acknowledgements

Special thanks is given to the Chair of the meeting, Dr David Vaughn, as well as to the rapporteur Dr Lewis Markoff. This conference was supported in part by PDVI.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29556

